Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 1 of 20

 
 

Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. Read More 
 
Trailing Twelve Months EPS: $11.36
2024 EPS Estimate: ($0.26)
2025 EPS Estimate: ($6.36)

Current Stock Price
$53.78
P/E Ratio
4.7
Consensus Rating
Moderate Buy
Ratings Breakdown
4 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$52.33 (2.7% Downside)

 

The Tesla Trade Is Back In Business (Ad)

If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.

Discover how to trade Tesla, simply follow this link here.